October 24, 2018 — Today, the U.S. Food and Drug Administration approved Xofluza (baloxavir marboxil) for the treatment of acute uncomplicated influenza (flu) in patients 12 years of age and older who have been symptomatic for no more than 48…Original Article
You may also like
FDA Approves Miudella (copper intrauterine system) for...
FDA Approves Ctexli (chenodiol) for Cerebrotendinous...
FDA Approves Merilog (insulin-aspart-szjj), a...
FDA Approves Xbryk (denosumab-dssb), a Biosimilar to...
FDA Approves Ospomyv (denosumab-dssb), a Biosimilar to...
FDA Approves Penmenvy (meningococcal groups A, B, C...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.